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OSTEPOROSIS
OSTEOPOROSIS—Health Policy
POS7
PERSISTENCE AND COMPLIANCE WITH BISPHOSPHONATE
THERAPY AMONG POST-MENOPAUSAL OSTEOPOROTIC
WOMEN
Cramer J1,Amonkar MM2, Hebborn A3, Suppapanya N2
1Yale University, West Haven, CT, USA; 2GlaxoSmithKline, Collegeville,
PA, USA; 3Hoffmann-La Roche, Nutley, NJ, USA
OBJECTIVES: To compare persistence and compliance of
weekly and daily bisphosphonate regimens among post-
menopausal osteoporotic women. METHODS: Post-
menopausal osteoporotic women (>45 years) prescribed a
once-weekly (QW) bisphosphonate (alendronate 35 or 70mg) or
once-daily (QD) bisphosphonate (alendronate 5 or 10mg or rise-
dronate 5mg) were identiﬁed from an administrative claims
database comprising 30 health plans. The QW and QD study
cohorts were followed for 12 months after the index prescrip-
tion. Medication possession ratio (MPR) was used to estimate
compliance while persistence was calculated as the number of
days from the initial prescription to a lapse of >30 days after
completion of the previous reﬁll. RESULTS: Between 1997 and
2002, a total of 2741 post-menopausal osteoporotic women who
were prescribed a bisphosphonate (alendronate QW = 731; alen-
dronate or risedronate QD = 2010) were identiﬁed (mean age =
63.7 years). Average MPR for the combined study cohorts was
60.6%. However, QW users had a signiﬁcantly higher MPR than
QD users (69.2% QW vs 57.6% QD, t = -7.51 p < 0.0001).
Treatment persistence was signiﬁcantly longer among the QW
users than QD users (227 vs 185 days to discontinuation, respec-
tively, log rank, p < 0.0001). Also, approximately 44% of weekly
bisphosphonate users and 32% of daily bisphosphonate users
persisted with their therapy at the end of 12 months. CON-
CLUSIONS: Post-menopausal women prescribed a weekly 
bisphosphonate regimen had signiﬁcantly higher rates of com-
pliance and longer persistence compared with those taking a
more frequent, daily dosing regimen. However, rates for both
regimens were less than desirable. These data demonstrate that
less frequent dosing increases persistency, which is needed to
obtain maximal long-term therapeutic beneﬁts.
POS8
PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE
IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POST-
MENOPAUSAL OSTEOPOROSIS
Penning-van Beest FJA1, Goettsch WG2, Erkens JA2, Herings RMC2
1PHARMO Institute, Utrecht, Utrecht,The Netherlands; 2PHARMO
Institute, Utrecht,The Netherlands
OBJECTIVES: The aim of this study was to compare the per-
sistence of use of daily and weekly administered bisphospho-
nates. METHODS: Data were obtained from the PHARMO
database, which includes linked drug-dispensing records and
hospital records of more than one million subjects in deﬁned
areas in The Netherlands. New female users of alendronate,
etidronate or risedronate aged 55 years and older in the period
January, 2000–September, 2003, were included in the study
cohort. One-year persistence of treatment was determined by
using episodes of bisphosphonate treatment based on the method
of Catalan. The effect of the dosing regimen and other determi-
nants including age, co-medication and fractures, on persistence
was assessed. RESULTS: The study cohort included 2124 new
users of bisphosphonates. Overall, 1-year persistence of bispho-
sphonates was low; only 911 (43%) users were persistent.
Etidronate users were less persistent (30%) than alendronate 
and risedronate users (46% and 42%, respectively). Among 
alendronate users, patients on the weekly regimen were more
persistent (52%) than those on the daily regimen (35%). A mul-
tivariate analysis including age, co-medication and fractures,
showed that patients using alendronate weekly were 2.26 times
more likely to be persistent (95%CI 1.66–3.09) compared to
patients using alendronate daily. CONCLUSIONS: Our results
indicate that persistence of bisphosphonate use is higher with a
less frequent dosing regimen. The improved persistence of the
weekly administered alendronate may theoretically be explained
by a reduced frequency to experience drug-related acute adverse
effects. However, persistence for both regimens can be con-
sidered to be suboptimal and leaves room for improvement.
POS9
EPIDEMIOLOGY OF OSTEOPOROSIS IN THE NETHERLANDS
(1993–2002)
Panneman MJM1, Goettsch WG1, Kramarz P2, Herings RMC3
1PHARMO Institute, Utrecht,The Netherlands; 2Pﬁzer, Walton Oaks,
UK; 3PHARMO Institute / Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Utrecht,The Netherlands
OBJECTIVES: To assess the prevalence and incidence of osteo-
porosis, determine recent and predict future time trends in the
Dutch population in the period 1993–2015. METHODS: Data
were obtained from the PHARMO database, which includes
linked drug-dispensing records and hospital records of more than
865,000 subjects in deﬁned areas in The Netherlands. Patients
(>45 years) who were hospitalised for osteoporosis (ICD9-CM:
733) or osteoporotic fractures (ICD-9-CM: 820, 812.0, 813.4,
805.2 and 805.4) and treated with glucocorticoids or anti-osteo-
porosis drugs (bisphosphonates, vitamin D, calcium, ralixofen,
HRT) between 1993 and 2002 were included. Prevalence of
osteoporosis was calculated as the total number of patients
having osteoporosis on a single ﬁxed day in a year (ﬁrst Wednes-
day of October). Incidence of osteoporosis was computed as the
number of new cases that met the inclusion criteria in a certain
year divided by total person-time contributed by the population
at risk. RESULTS: A total of 32,219 patients were included in
this cohort. Prevalence of osteoporosis increased from 36 in
1994 to 56 in 2002 per 1000 inhabitants. Incidence declined 
in the same period from 8.7 to 7.0 (per 1000 inhabitants.).
Extrapolations based on demographic changes in the future indi-
cate that prevalence of osteoporosis will increase up to more than
65 (per 1000 inhabitants) in 2015. CONCLUSIONS: Prevalence
of osteoporosis has been continuously increasing over the past
decade. Our data show that the pace of this increase slowly
declines probably due to increased awareness and screening that
leads to a decrease in the size of the ‘pool’ of undetected osteo-
porotic patients. Ageing of the population is becoming the pre-
dominant contributor to a further increase of the osteoporosis
prevalence in the future causing great social and economic
burden to the society. Prevention of osteoporosis and its conse-
quences is critical to reducing this burden.
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PPN13
THE UNDER TREATMENT OF DEPRESSION IN CHRONIC PAIN
Sampson J, Marsh B
VA Medical Center, Gainesville, FL, USA
OBJECTIVES: Depression has been reported to be highly asso-
ciated with chronic pain. It is believed that chronic pain causes
725Abstracts
depression. Our objective was to see if depression was present
in patients undergoing treatment for chronic pain with opioids
and if improving pain, improves depression. METHODS: A
standardized depression scale was administered to chronic stable
pain patients on opioids for chronic non-malignant pain. They
were scored and ranked. RESULTS: Out of 98 patients, only
15% had minimal to no depression by standardized testing.
There was good correlation with subsequent clinical evaluation.
Eighty-ﬁve percent (85%) had mild to severe depression. Those
with moderate to severe depression were referred for specialty
consultation. CONCLUSIONS: Depression is common in
chronic pain and the level of depression may not be predicted by
level of pain, analgesic, anti-depressant useage, or mental health
follow-up. Depression is easily missed and under-treated.
Depression does not always respond to the concomitant treat-
ment of pain. Patients with chronic pain should be regularly
screened for depression and appropriately referred for care.
PPN1
ESTIMATING THE INCIDENCE AND COSTS OF TREATING
ADVERSE EVENTS IN PATIENTS TREATED WITH STRONG
OPIOIDS FOR CHRONIC NON-MALIGNANT PAIN
Morris J, Berry P
Napp Pharmaceuticals, Cambridge, UK
OBJECTIVE: Patients receiving strong opioids for chronic non-
malignant pain frequently experience adverse events, placing a
considerable burden on the patient and health care system. Evi-
dence suggests adverse event rates may vary between treatments.
METHODS: Patients treated with strong opioids for non-
malignant pain were identiﬁed using the General Practice
Research Database (GPRD). Three cohorts were identiﬁed: oral
oxycodone, oral modiﬁed release morphine, transdermal fen-
tanyl. Patients were matched for age, gender, morphine equiva-
lent dose and prior exposure to strong opioids. Adverse events
of interest were constipation and nausea and vomiting. Six
months of data were collected for each patient either side of their
ﬁrst prescription date (index date) for a strong opioid. Incidence
of treated adverse events was identiﬁed by prescription of laxa-
tives and anti-emetics during the 6-month post index, where no
prescription was present during the 6-month pre-index. Treat-
ment costs were estimated using the BNF. The chi square test
was used to test for differences in adverse event rates. RESULTS:
Incidence of constipation requiring treatment was estimated at
15% in the oxycodone cohort, 15% in the fentanyl cohort and
22% in the morphine cohort. Rates for oxycodone and fentanyl
were signiﬁcantly lower than morphine (p < 0.05). For nausea
and vomiting rates were 11%, 14%, and 14% respectively with
no signiﬁcant differences between cohorts. Mean treatment cost,
per case of constipation, was £19.34 for oxycodone, £41.71 for
fentanyl and £31.79 for morphine. For nausea and vomiting
costs were £13.10, £22.06 and £11.09. CONCLUSION: Patients
treated with morphine for non-malignant pain in this study were
more likely to be treated for constipation compared to oxy-
codone or fentanyl. Treatment for nausea and vomiting was
equally likely across treatment cohorts. Differences were
observed in the mean cost associated with adverse event treat-
ment. Further research would be valuable to conﬁrm the ﬁnd-
ings of this study.
PPN2
RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN
CONDITIONS BEFORE AND DURING TREATMENT WITH
LONG-ACTING OPIOIDS IN GERMANY
Burkowitz J, Brüggenjürgen B
Alpha Care GmbH, Celle, Germany
OBJECTIVES: Although use of long-acting opiod analgesics has
increased for chronic pain, little is known about treatment 
patterns. Purpose of this study was to compare ofﬁce-based 
utilisation data before and after initiating treatment with 
different long-acting opioids. METHODS: Retrospective analy-
sis of Disease Analyzer (MediPlus) data over 5 years for patients
with malignant diseases and orthopaedic diseases/chronic pain.
Patients have not been treated with opioids in the 18 months
before prescription. Observation period for resource utilisation
(outpatient consultations, referrals, dug costs) started 6 months
before and ended 6 months after ﬁrst index prescription for the
long-acting opioid of interest. RESULTS: Corresponding to the
course of the disease number of referrals, consultations, costs of
other drugs except of analgesics increased after initial prescrip-
tion of opioids. When opioids were administered, costs for other
analgesics decreased slightly compared to the pre-opioid period.
Drug costs differed signiﬁcantly. Highest opioid costs were deter-
mined for patients with malignant diseases which were treated
with fentanyl (mean 681€ in ﬁrst six months), followed by oxy-
codone (412€) and morphine (321€). Costs for opiod treatment
for patients with non-malignant chronic pain and orthopedic
conditions were 589€ (fentanyl), 370€ (oxycodone) and mor-
phine (243€) respectively. No signiﬁcant differences for costs for
other medication were found. Patients treated with oxycodone
showed signiﬁcant less consultations compared to fentanyl or
morphine. CONCLUSION: Type of opioid is an important
factor for costs of treatment of chronic pain in the ofﬁce-based
setting in Germany. The analysis indicates that other resource
utilization like consultation of physician could also be inﬂu-
enced. Due to the observational and retrospective nature of the
database study patient reported outcomes were not included.
Thus these outcomes and direct costs from hospitals associated
with long-acting opioids treatment would merit further analysis
in Germany.
PPN3
AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENT-
CONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN
ACADEMIC MEDICAL CENTER
Zhang M1,Viscusi E2, Costello A2,Vallow S3, Johnson N4
1Ortho-McNeil Pharmaceutical, Raritan, NJ, USA; 2Thomas Jefferson
University, Philadelphia, PA, USA; 3Janssen Medical Affairs, LLC,
Titusville, NJ, USA; 4Outcomes Research and Design, Inc, Houston,
TX, USA
OBJECTIVES: Intravenous patient-controlled analgesia (IV
PCA) is widely used for postoperative pain management. The
objectives of this pilot observational study were to deﬁne the
tasks and personnel required for IV PCA administration and to
identify problems arising with use of this modality. METHODS:
This study was conducted at a single site academic medical center
in Philadelphia, PA, USA. Process ﬂow diagrams were developed
based on interviews and observations conducted in the central
supply, biomedical engineering, pharmacy, and nursing depart-
ments. The diagrams mapped all steps in the process of IV PCA
administration within each department. Problems related to IV
PCA administration were also recorded. RESULTS: Forty-two
patients who underwent hip replacement surgery were selected
for observation. Central supply collected, cleaned, and delivered
IV PCA pumps to appropriate locations, and delivered malfunc-
tioning pumps to biomedical engineering. Biomedical engineer-
ing evaluated malfunctioning pumps and performed routine
maintenance on all pumps. Pharmacy prepared IV PCA syringes
and delivered them to the nursing units. Nursing staff processed
IV PCA orders, obtained pumps and set them up, redressed or
restarted IV lines, educated patients, discontinued PCA, and
